Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ferry Ossendorp

Showing results (31-40 of 162) with videos related to

Pageof 17
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 16, 2016
Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticlesEleni Maria Varypataki, Ana Luisa Silva, Christophe Barnier-Quer, et al.
Current Pharmaceutical Design|September 2, 2015
Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of CancerSima Rahimian, Marieke F Fransen, Jan Willem Kleinovink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2013
Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effectsMarieke F Fransen, Tetje C van der Sluis, Ferry Ossendorp, et al.
Science Advances|July 14, 2023
Genome-wide CRISPR screens define determinants of epithelial-mesenchymal transition mediated immune evasion by pancreatic cancer cellsYuanzhuo Gu, Zhengkui Zhang, Marcel G M Camps, et al.
Nature Reviews. Cancer|March 12, 2016
Vaccines for established cancer: overcoming the challenges posed by immune evasionSjoerd H van der Burg, Ramon Arens, Ferry Ossendorp, et al.
The Journal of Clinical Investigation|July 28, 2015
Therapeutic cancer vaccinesCornelis J M Melief, Thorbald van Hall, Ramon Arens, et al.
Seminars in Immunology|May 28, 2013
Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancerRamon Arens, Thorbald van Hall, Sjoerd H van der Burg, et al.
Pharmaceutics|July 27, 2022
Bacterial Cellulose as Drug Delivery System for Optimizing Release of Immune Checkpoint Blocking AntibodiesChih Kit Chung, Uwe Beekmann, Dana Kralisch, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 17, 2018
Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrencesChih Kit Chung, C G Da Silva, Dana Kralisch, et al.
Molecular Immunology|July 2, 2014
Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoireCláudia C Oliveira, Marjolein Sluijter, Bianca Querido, et al.
Pageof 17

Showing results (31-40 of 162) with videos related to

Sort By:
Pageof 17
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 16, 2016
Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticlesEleni Maria Varypataki, Ana Luisa Silva, Christophe Barnier-Quer, et al.
Current Pharmaceutical Design|September 2, 2015
Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of CancerSima Rahimian, Marieke F Fransen, Jan Willem Kleinovink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2013
Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effectsMarieke F Fransen, Tetje C van der Sluis, Ferry Ossendorp, et al.
Science Advances|July 14, 2023
Genome-wide CRISPR screens define determinants of epithelial-mesenchymal transition mediated immune evasion by pancreatic cancer cellsYuanzhuo Gu, Zhengkui Zhang, Marcel G M Camps, et al.
Nature Reviews. Cancer|March 12, 2016
Vaccines for established cancer: overcoming the challenges posed by immune evasionSjoerd H van der Burg, Ramon Arens, Ferry Ossendorp, et al.
The Journal of Clinical Investigation|July 28, 2015
Therapeutic cancer vaccinesCornelis J M Melief, Thorbald van Hall, Ramon Arens, et al.
Seminars in Immunology|May 28, 2013
Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancerRamon Arens, Thorbald van Hall, Sjoerd H van der Burg, et al.
Pharmaceutics|July 27, 2022
Bacterial Cellulose as Drug Delivery System for Optimizing Release of Immune Checkpoint Blocking AntibodiesChih Kit Chung, Uwe Beekmann, Dana Kralisch, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 17, 2018
Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrencesChih Kit Chung, C G Da Silva, Dana Kralisch, et al.
Molecular Immunology|July 2, 2014
Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoireCláudia C Oliveira, Marjolein Sluijter, Bianca Querido, et al.
Pageof 17